KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Before Jan 1, 2032 59%Führend unter 6 Optionen
Marktqualitat
47 / 100
Niedrige Qualität24h-Volumen
81,9 €
Liquidität
5749,8 €
Mittlere LiquiditätSpread
5.0 pt
Mittlerer SpreadMarktdaten
Aktualisiert vor 10 Minuten
14. Mai 26, 02:00 UTC1. Jan. 28, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will the FDA approve cytisinicline for smoking cessation?
KalshiWill the FDA approve CagriSema?
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any strain of influenza before 2028?
Manifold MarketsRegeln
If the FDA approves midomafetamine / MDMA for PTSD for marketing the named outcome, then the market resolves to Yes.
Abwicklung über:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Offene Märkte
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No+0.4pt97%
- Yes-0.4pt3%
- Gesamtvolumen
- 15,7 Mio. €
- 24h-Volumen
- 52.229,8 €
KALSHIMeasles cases in 2026?
- Above 4000+2.0pt99%
- Above 300099%
- Above 600061%
+2 weitere Ergebnisse
- Gesamtvolumen
- 870.445,2 €
- 24h-Volumen
- 2087,6 €
POLYMARKETNew pandemic in 2026?
- No-1.0pt93.1%
- Yes+1.0pt6.9%
- Gesamtvolumen
- 922.473,3 €
- 24h-Volumen
- 1758,2 €
KALSHICyclosporiasis cases reported in the US in 2026?
- Above 18k99%
- Above 6k99%
- Above 10k99%
+12 weitere Ergebnisse
- Gesamtvolumen
- 32.412,1 €
- 24h-Volumen
- 1299,1 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes+0.4pt3%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 933,9 €
KALSHIHealthcare AI adoption in September
- Above 43%87%
- Above 43.75%59%
- Above 45%14%
+4 weitere Ergebnisse
- Gesamtvolumen
- 810,1 €
- 24h-Volumen
- 767 €
- FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- Measles cases in U.S. by September 30?
- What will the average number of measles cases be during Trump's term?
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Will the FDA approve any psychedelic substance for medical use this year?
- Pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- Ebola: new country confirmed before October 1?
Häufige Fragen
- Wie stehen die aktuellen Quoten für Will the FDA approve MDMA for PTSD??
- Kalshi bewertet Before Jan 1, 2032 mit 59% (Stand: 11. September 2026).
- Wann wird Will the FDA approve MDMA for PTSD? entschieden?
- Will the FDA approve MDMA for PTSD? soll am 1. Januar 2028 entschieden werden.
- Wie wird Will the FDA approve MDMA for PTSD? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA approves midomafetamine / MDMA for PTSD for marketing the named outcome, then the market resolves to Yes.